Abstract
The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients’ exposure to topical bovine thrombin administered during surgery procedures. However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases.
Similar content being viewed by others
References
Knoble P, Lechner K (1998) Acquired factor V inhibitors. Bailliere’s Clin Haematol 11:305–318
Emori Y, Sakugawa M, Niiya K et al (2002) Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 13:555–559
Wiwanitkit V (2006) Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost 12:485–488
Morris CJ, Curris N (2009) Acquired factor V inhibitor in a critically ill patient. Anaesthesia 64:1014–1017
Franchini M, Gandini G, Di Paolantonio T et al (2005) Acquired hemophilia A: a concise review. Am J Hematol 80:55–63
Franchini M, Targher G, Montagnana M, Lippi G (2008) Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 395:14–18
Ortel T (1999) Clinical and laboratory manifestations of antifactor V antibodies. J Lab Clin Med 133:326–334
Favaloro EJ, Bonar R, Duncan E et al (2006) Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 96:73–78
Favaloro EJ, Posen J, Ramakrishna R et al (2004) Factor V inhibitors: rare or not so uncommon? A multilaboratory investigation. Blood Coagul Fibrinolysis 15:637–647
Miesbach W, Voigt J, Peetz D, Scharrer I (2003) Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin 98:339–343
Lucia JF, Aguilar C (2005) A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 11:178–180
Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y (2003) Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 14:87–93
Koyama JA, Saito T, Kusano T, Hirosawa S (1995) Factor V inhibitor associated with Sjogren’s syndrome. Br J Haematol 89:893–896
Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26
Banninger H, Hardegger T, Tobler A et al (1993) Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 85:528–532
Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH (2001) Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233:88–96
Lu L, Liu Y, Wei J, Zhang L, Yang R (2004) Acquired inhibitor of factor V: first report in China and literature review. Haemophilia 10:661–664
Leus B, Devreese K, Van den Bossche J, Malfait R (2006) Factor V inhibitor: case report. Blood Coagul Fibrinolysis 17:585–587
Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T (2000) Hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 15:378–382
Bowman LJ, Anderson CD, Chapman WC (2010) Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 36:477–484
Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859
Feinstein DI (1978) Acquired inhibitors of factor V. Thromb Haemost 39:663–674
Ferguson JH, Johnston CL, Howell DA (1958) A circulating inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood 13:382–397
Lopez V, Pflughaupt R, Butler R (1968) A specific inhibitor of human clotting factor V. Acta Haematol 40:275–285
Hundley DA, Duncan BM (1969) A circulating anticoagulant specific for factor V. Pathology 1:265–272
Feinstein DI, Rapaport SI, McGehee WG, Patch MJ (1970) Factor V anticoagulants: clinical, biochemical and immunological observations. J Clin Invest 49:1578–1588
Feinstein DI, Rapaport SI, Chong MMY (1973) Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 78:385–388
Onuora CA, Lindenbaum J, Nossel HL (1973) Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 265:407–417
Nilsson IM, Hedner U, Ekberg M, Denneberg T (1974) A circulating anticoagulant against factor V. Acta Med Scand 195:73–77
Stenbjerg S, Husted S, Mygind K (1975) A circulating factor V inhibitor: possible side effect of treatment with strepromycin. Scand J Haematol 14:280–285
Crowell EB (1975) Observations on a factor V inhibitor. Br J Haematol 29:397–404
Bryning K, Leslie J (1977) Factor V inhibitor and bullous pemphigoid. Br Med J 2:677–678
Coots MC, Muhleman AF, Glueck HI (1978) Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 4:193–206
Lane TA, Shapiro SS, Burka ER (1978) Factor V antibody and disseminated intravascular coagulation. Ann Intern Med 89:182–185
Lust A, Bellon A (1978) A circulating anticoagulant against factor V. Acta Clin Belg 33:62–65
Chediak J, Ashenhurst JB, Garlick I, Desser RK (1980) Sucessful management of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 56:835–841
Abe T, Kazama M, Itokazu K et al (1980) A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII bypassing activity preparation FEIBA. Rinsho Ketsueki 21:1664–1673
Hida K, Sakamoto S, Takaku F et al (1980) A case of acquired coagulopathy due to factor V inhibitor. Rinsho Ketsueki 21:1589–1596
Lerolle D, Dreyer-Dufer C, Allain JP (1981) A circulating inhibitor specific to factor V. Clinical, biological and therapeutic study. Nouv Presse Med 10:1483–1487
Kuto M, Izuchi Y, Deguchi K, Morito T, Lee C, Wada H (1981) An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Nippon Ketsueki Gakkai Zasshi 44:938–950
Vickars LM, Coupland RW, Naiman SC (1985) The response of an acquired factor V inhibitor to activated factor IX concentrate. Transfusion 25:51–53
Chong LL, Wong YC (1985) A case of factor V inhibitor. Am J Hematol 19:395–399
Chiu HC, Rao AK, beckett C, Colman RW (1985) Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 65:810–818
Nesheim ME, Nichols WL, Cole TL et al (1986) Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77:405–415
Brandt J, Britton A, Kraut E (1986) A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 110:224–227
Lazarchick J, Wolff M, Pepkowitz SH, Kizer J, Romein LA (1986) Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 110:448–451
Massignon D, Roullit S, Espinouse D, Coeur P (1989) Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention. Ann Fr Anesth Reanim 81:70–72
Okajima A, Horii J, Nasu K et al (1989) Factor V inhibitor with double cancer. Rinsho Ketsueki 30:514–519
Grigg AP, Dauer R, Thurlow PJ (1989) Bleeding due to an acquired inhibitor of platelet associated factor V. Aust NZ J Med 19:310–314
Taillan B, Fuzibet JB, Vinti H et al (1989) Factor V inhibitor in celiac disease. Am J Med 87:360
Gordon B, haire W, Duggan M, Langnas A (1991) Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 88:156–159
Buclin T, Schmidt PM, Hauert J, Winkel L, Chapuis G, Bachmann F (1992) Acquired factor V inhibitor treated with intravenous immunoglobulins. Schweiz Med Wochenschr 122:1968–1970
Kapur A, Kelsey PR, Isaacs PET (1993) Factor V inhibitor in thrombosis. Am J Hematol 42:384–388
Smid WM, de Wolf JTM, Nijland JH, Bom VJJ, van der Meer J (1994) Sever bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coagul Fibrinolysis 5:133–137
Denis A, Baudeau C, Verdy E, Couderc R, Rondeau E, Sraer JD (1995) Acquired circulating anticoagulant with anti-factor V activity in AIDS: first case report. Nouv Rev Fr Hematol 37:165–169
Tribl B, Knobl P, Derfler K et al (1995) Rapid elimination of a high-titer spontanoues factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression. Ann Hematol 71:199–203
George S, Nagabhushana MS, Cyran EM (1995) Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 49:98–100
Suehisa E, Toku M, Akita N et al (1995) Study of an antibody against F1F2 fragment of human factor V in a patient with Hashimoto’s disease and bullous pemphigoid. Thromb Res 77:63–68
Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA (1996) Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 51:315–318
Brickner LA, Scannell KA, Sahud MA (1996) Acquired factor V inibito in a patient with acquired human immunodeficiency syndrome. Am J Hematol 52:332–333
Van Spronsen DJ, Oosting JD, Hoffmann JJML, Breed WPM (1998) Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 76:49–50
Kamphuisen PW, Haan J, Rosekrans PCM, van der Meer FJM (1998) Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features. Am J Hematol 57:176–178
Smith JD, Sindhi R, Rogers R, Lazarchick J (1998) Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 28:280–282
Shastri KA, Ho C, Logue G (1999) An acquired factor V inhibitor: clinical and laboratory features. J Med 30:357–366
Leroy-Matheron C, Mallat A, Duvoux C et al (1999) Inhibitor against coagulation factor V after liver transplantation. Transplantation 68:1054–1056
Jansen M, Schmaldienst S, Banyai S et al (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112:91–97
Bayani N, Rugina M, Haddad-Vergnes L, Lelong F (2002) High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 71:33–36
Takaku T, Kuriyama Y, Shoji N et al (2002) Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis. Rinsho Ketsueki 43:1050–1054
Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A (2002) Isolation and characterization of an antifactor V antibody causino activated protein C resistance from a patient with severe thrombotic manifestations. Blood 99:3985–3992
Hasegawa M, Tanaka T, Kii T et al (2003) Acquired inhibitor against coagulation factor V with severe hematuria. Rinsho Ketsueki 44:933–939
Okoshi Y, Akiyama H, Inoue T et al (2003) A long-lasting idiopathic factor V inhibitor. Rinsho Ketsueki 44:14–18
Ajzner E, Balogh I, Haramura G et al (2003) Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 1:943–999
de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C (2003) High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 74:187–190
Lian EC, Tzakis AG, Andrews D (2004) Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 77:363–365
Tukić L, Stamatović D, Tarabar O, Elez M, Zorić M, Mandić-Radić S (2005) Acquired factor V inhibitors in a polytraumatized patient. Vojnosanit Pregl 62:587–590
Godart B, Boinot C, Remblier C, Hajjar A, Beauchant M (2006) Acquired factor V inhibitor associated with valproic acid use in a cirrhotic patient. Gut 55:134–135
Perdekamp MT, Rubenstein DA, Jesty J, Hultin MB (2006) Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assys. Blood Coagul Fibrinolysis 17:593–597
Gacina P, Kusec R, Carzavec D, Raic B, Stancic V (2006) Acquired factor V inhibitor: a case report. Acta Clin Croat 45:199–201
Endo H, Kawauchi K, Tomimatsu M et al. (2007) Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers. Intern Med 46:621–625
Maughan EO, Wilson J, Wilde JT (2007) Spontaneous resolution of acquired factor V inhibitor associated with ovarian carcinoma. Int J Lab Hematol 29:316–319
Milojkovic D, Patel R, Ford E, Arya R, Mufti G (2007) Acquired factor V inhibitor after hematopoietic stem cell transplantation. Thromb Haemost 98:685–687
Shimizu I, Ichikawa N, Yotsumoto M, Sumi M, Ueno M, Kobayashi H (2008) High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors. Rinsho Ketsueki 49:413–416
Jeimy SB, Krakow EF, Fuller N, Tasneem S, Hayward CPM (2008) An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. J Thromb Haemost 6:395–397
Lebrun A, Leroy-Matheron C, Arlet JB, Bartolucci P, Michel M (2008) Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol 83:163–164
William BM (2008) Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor. Blood Coagul Fibrinolysis 19:327–328
Gadelha T, Aquino JHW, Silva EA, Santos FL, de Oliveira MHFC (2008) The diversity in clinical presentation of acquired factor V inhibitor, two case reports. Acta Haematol 119:108–110
Kindler S, Siegemund T, Fuhrer D, Petros S (2008) Thrombin generation assay in a patient with acquired factor V inhibitor. J Thromb Haemost 6:1985–1987
Shanmugam H, Jayaranee S, Eow GI (2010) A case report of an acquired inhibitor to coagulation factor V. Haemophilia [Epub ahead of print]
Tessier-Marteau A, Croquefer S, Meziani F, Cau S, Asfar P, Macchi L (2010) Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation. Am J Hematol 85:145–146
Franchini M, Lippi G (2010) Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Haemost 36:485–492
Yu Z, Lennon VA (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227–228
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Franchini, M., Lippi, G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31, 449–457 (2011). https://doi.org/10.1007/s11239-010-0529-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-010-0529-6